DRF 10945

Drug Profile

DRF 10945

Latest Information Update: 07 Jul 2010

Price : $50

At a glance

  • Originator Dr Reddys Laboratories
  • Developer Perlecan Pharma
  • Class Antihyperlipidaemics
  • Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Lipid metabolism disorders

Most Recent Events

  • 07 Jul 2010 Discontinued - Phase-I for Lipid metabolism disorders in Canada (PO)
  • 07 Jul 2010 Discontinued - Preclinical for Lipid metabolism disorders in France (PO)
  • 26 May 2009 DRF 10945 is available for licensing (http://www.drreddys.com/investors/pdf/Fiscal2008Form20F.pdf)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top